Lenzilumab for COVID-19 Improves Survival Without Ventilation in Phase 3 Trial

Retrieved on: 2021-05-26 13:20:22

Tags for this article:

Medicine

Medical specialties

Pharmaceutical industry

Monoclonal antibodies

Click the tags to see associated articles and topics

Lenzilumab for COVID-19 Improves Survival Without Ventilation in Phase 3 Trial. View article details on HISWAI: https://www.contagionlive.com/view/lenzilumab-for-covid-19-improves-survival-without-ventilation-in-phase-3-trial

Excerpt

Lenzilumab, a monoclonal antibody drug developed by Humanigen, appeared safe and effective for treating coronavirus disease 2019 (COVID-19), ...

Article found on: www.contagionlive.com

View Original Article